Conclusion of Valeant's (VRX) Ad Hoc Committee Review is Positive Development - Moody's

Allergan (AGN) Could Move on Valeant's (VRX) Bausch + Lomb Unit if Pfizer (PFE) Deal Fails - Analyst

BTIG issued brief commentary on Allergan (NYSE: AGN) following the U.S. Treasury's tax inversion actions on Monday night.

Analyst Timothy Chiang commented on potential routes for Allergan if its deal with Pfizer (NYSE: PFE)... More

Valeant (VRX) Could Be on the Verge of a Significant Inflection Point - BMO Capital

BMO Capital analyst Alex Arfaei said Valeant Pharmaceuticals (NYSE: VRX) could be on the verge of a significant inflection point after the ad hoc committee of the board of directors believes that its review of various Philidor and related accounting matters is complete and that it has not identified any additional items that would require restatements beyond those required by matters previously disclosed. The company intend to file its Form 10-K on or before April 29. The firm maintained its Market Perform rating and price target of $66.00.

Arfaei views the news as positive: "Our... More

Valeant Pharma's (VRX) Ad Hoc Committee Completes Review; No Additional Items for Restatement Identified

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that the ad hoc committee of the board of directors (the "Ad Hoc Committee") believes that its review of various Philidor and related accounting matters is complete, and that it has not identified any additional items that would require restatements beyond those required by matters previously disclosed.

Given the completion of the review, Valeant's Board has determined to dissolve the Ad Hoc Committee and that the 12... More

Valeant Pharma (VRX) said to terminate Addyi sales force in reorganization - Bloomberg

Valeant Pharma (NYSE: VRX) said to terminate Addyi sales force in reorganization, according to Bloomberg.

Valeant said it has received increasing feedback from doctors that we have too many people calling on them to discuss closely related product.

Some Valeant Pharma (VRX) Creditors Said Against Proposal to Relax Loan Pact

(Updated - April 4, 2016 4:00 PM EDT)

Some Valeant Pharma (NYSE: VRX) creditors said to resist proposal to relax loan pact, according to Bloomberg. Some lenders are said looking for higher fees and rates, sources noted.

UPDATE - Valeant... More